← All news
Markets
Merck reveals study success, and possible safety worries, for eye drug hopeful
A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.
Covered by 1 outlet
All coverage · 1 article